Isovaleric Acidemia Market

Market Overview:

The 7 major isovaleric acidemia markets are expected to exhibit a CAGR of 4.39% during 2024-2034.

The isovaleric acidemia market has been comprehensively analyzed in IMARC's new report titled "Isovaleric Acidemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Isovaleric acidemia (IVA) refers to a rare inherited metabolic disorder characterized by the body's incapability to properly break down the amino acid leucine. This results in the buildup of isovaleric acid and its derivatives in tissues and bodily fluids. The disorder occurs due to a deficiency of the enzyme isovaleryl-CoA dehydrogenase, which is essential for the breakdown of leucine. The symptoms of the ailment typically appear in infancy or early childhood and can differ from mild to severe. These indications may include poor feeding, vomiting, a distinctive sweaty foot odor, lethargy, developmental delays, muscle weakness, and even life-threatening metabolic crises, which can lead to coma, epilepsy, and death if not promptly treated. The diagnosis of IVA often involves genetic testing to identify the variations in the genes causing the disorder. A healthcare professional might also perform confirmatory tests, including analyzing urine and blood for increased concentrations of isovaleric acid and its derivatives.

The increasing cases of genetic mutations, leading to the deficiency of the isovaleryl-CoA dehydrogenase enzyme are primarily driving the isovaleric acidemia market. In addition to this, the inflating utilization of effective treatments, such as dietary management to limit the intake of certain amino acids and the administration of carnitine to facilitate the excretion of toxic metabolites, is also creating a positive outlook for the market. Moreover, the widespread adoption of newborn screening programs, enabling early detection and intervention, is further bolstering the market growth. These programs aid in identifying patients shortly after birth, allowing for timely implementation of therapeutic strategies and minimizing potential complications. Apart from this, the rising usage of supportive therapies like physical therapy and speech therapy, aimed at enhancing motor skills, communication, and overall quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of liver transplant procedures, which can offer a more permanent solution for severe cases of IVA, is also augmenting the market growth. Furthermore, the escalating demand for gene therapy, since it involves introducing functional genetic material to correct the underlying genetic mutations responsible for the disorder, is expected to drive the isovaleric acidemia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the isovaleric acidemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for isovaleric acidemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the isovaleric acidemia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the isovaleric acidemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the isovaleric acidemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current isovaleric acidemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the isovaleric acidemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the isovaleric acidemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the isovaleric acidemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of isovaleric acidemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of isovaleric acidemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of isovaleric acidemia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with isovaleric acidemia across the seven major markets?
• What is the size of the isovaleric acidemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of isovaleric acidemia?
• What will be the growth rate of patients across the seven major markets?
   

Isovaleric Acidemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for isovaleric acidemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the isovaleric acidemia market?
• What are the key regulatory events related to the isovaleric acidemia market?
• What is the structure of clinical trial landscape by status related to the isovaleric acidemia market?
• What is the structure of clinical trial landscape by phase related to the isovaleric acidemia market?
• What is the structure of clinical trial landscape by route of administration related to the isovaleric acidemia market?